company background image
KPTI logo

Karyopharm Therapeutics NasdaqGS:KPTI Stock Report

Last Price

US$1.48

Market Cap

US$170.3m

7D

5.7%

1Y

-62.2%

Updated

27 Mar, 2024

Data

Company Financials +

Karyopharm Therapeutics Inc.

NasdaqGS:KPTI Stock Report

Market Cap: US$170.3m

KPTI Stock Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.

KPTI fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Karyopharm Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Karyopharm Therapeutics
Historical stock prices
Current Share PriceUS$1.48
52 Week HighUS$4.87
52 Week LowUS$0.62
Beta0.0025
1 Month Change12.98%
3 Month Change60.29%
1 Year Change-62.24%
3 Year Change-85.93%
5 Year Change-73.81%
Change since IPO-90.78%

Recent News & Updates

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Feb 23
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Recent updates

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Feb 23
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Feb 05

Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Apr 17
Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Karyopharm: Market Is Overlooking Growth

Oct 07

Karyopharm Therapeutics Q2 2022 Earnings Preview

Aug 03

Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU

Jul 20

Karyopharm: Another 2 Year Wait For Data

May 05

Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates

Feb 19

Karyopharm Therapeutics: Unjustified Sell-Off Provides An Opportunity To Reload My Position

Dec 04

Karyopharm Therapeutics: After Years Of Waiting I'm Ready To Join The Bulls

Sep 16

Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Aug 07
Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Shareholder Returns

KPTIUS BiotechsUS Market
7D5.7%0.9%0.4%
1Y-62.2%10.3%28.8%

Return vs Industry: KPTI underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: KPTI underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is KPTI's price volatile compared to industry and market?
KPTI volatility
KPTI Average Weekly Movement18.8%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: KPTI's share price has been volatile over the past 3 months.

Volatility Over Time: KPTI's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2008325Richard Paulsonhttps://www.karyopharm.com

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Karyopharm Therapeutics Inc. Fundamentals Summary

How do Karyopharm Therapeutics's earnings and revenue compare to its market cap?
KPTI fundamental statistics
Market capUS$170.30m
Earnings (TTM)-US$143.10m
Revenue (TTM)US$146.03m

1.2x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KPTI income statement (TTM)
RevenueUS$146.03m
Cost of RevenueUS$4.94m
Gross ProfitUS$141.09m
Other ExpensesUS$284.19m
Earnings-US$143.10m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.24
Gross Margin96.62%
Net Profit Margin-97.99%
Debt/Equity Ratio-222.7%

How did KPTI perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.